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Abstract
Background: Sugammadex reverses neuromuscular block (NMB) through binding aminosteroid neuromuscular
blocking agents. Although sugammadex appears to be highly selective, it can interact with other drugs, like
corticosteroids. A prospective single-blinded randomized clinical trial was designed to explore the significance
of interactions between dexamethasone and sugammadex.
Methods: Sixty-five patients who were anesthetized for elective abdominal or urological surgery were included.
NMB was assessed using train-of-four stimulation (TOF), with rocuronium used to maintain the desired NMB depth.
NMB reversal at the end of anaesthesia was achieved using sugammadex. According to their received antiemetics,
the patients were randomized to either the granisetron or dexamethasone group. Blood samples were taken before
and after NMB reversal, for plasma dexamethasone and rocuronium determination. Primary endpoint was time from
sugammadex administration to NMB reversal. Secondary endpoints included the ratios of the dexamethasone and
rocuronium concentrations after NMB reversal versus before sugammadex administration.
Results: There were no differences for time to NMB reversal between the control (mean 121 ± 61 s) and the
dexamethasone group (mean 125 ± 57 s; P = 0.760). Time to NMB reversal to a TOF ratio ≥0.9 was significantly
longer in patients with lower TOF prior to sugammadex administration (Beta = −0.268; P = 0.038). The ratio between
the rocuronium concentrations after NMB reversal versus before sugammadex administration was significantly
affected by sugammadex dose (Beta = −0.375; P = 0.004), as was rocuronium dose per hour of operation (Beta = −0.
366; p = 0.007), while it was not affected by NMB depth before administration of sugammadex (Beta = −0.089; p = 0.
483) and dexamethasone (Beta = −0.186; p = 0.131). There was significant drop in plasma dexamethasone after
sugammadex administration and NMB reversal (p < 0.001).
Conclusions: Administration of dexamethasone to anesthetized patients did not delay NMB reversal by sugammadex.
Trial registration: The trial was retrospectively registered with The Australian New Zealand Clinical Trials Registry
(ANZCTR) on February 28th 2012 (enrollment of the first patient on February 2nd 2012) and was given a trial ID
number ACTRN12612000245897 and universal trial number U1111-1128-5104.
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Background
Sugammadex is the first selective muscle-relaxant-binding
agent that acts by forming a complex with aminosteroid
neuromuscular blocking agents (e.g., rocuronium). This
results in a rapid decrease in free rocuronium in the
plasma [1], and causes a shift from the acetycholine recep-
tors in the neuromuscular junction, down the concentra-
tion gradient into the plasma. This allows rapid and
effective reversal of neuromuscular block (NMB) of any
depth. Sugammadex is excreted both rapidly and virtually
unchanged via the urine [1, 2], as is the rocuronium–
sugammadex complex, which resembles the pharmacoki-
netic features of sugammadex [1, 3, 4].
Corticosteroids have wide applications in anaesthesiology,
as they are one of the most commonly prescribed drugs in
patients with chronic diseases [5]. Furthermore, corticoste-
roids have an important role in states of hyper-reactive
airway [6], anaphylaxis [7, 8], septic shock [9, 10], and
laryngeal [11], cerebral [12, 13], and surgical edema [14],
and they are also used in conjunction with multimodal
analgesia [15–17] and for the prevention of postoperative
nausea and vomiting [18–20]. Among the corticosteroids,
dexamethasone is the most commonly used for the treat-
ment of oedema and analgesia, and for the prevention of
postoperative nausea and vomiting. Structurally, dexa-
methasone closely resembles the aminosteroid neuromus-
cular blocking agents, and therefore concerns have been
raised about possible interference of such corticosteroids in
the action of sugammadex [21–24].
There are two types of possible interactions of drugs
with sugammadex that need to be taken into consider-
ation: capturing and displacement. Capturing interac-
tions can occur with oral contraceptives, where their
free and active concentrations can be reduced by sugam-
madex coadministration to such an extent that it has the
effect of missing a daily dose of contraceptives [25, 26].
Displacement potential was tested in early in vitro stud-
ies by Zhang [25], where isothermal titration calorimetry
showed that over 40 lipophilic, steroid, and non-steroid
drugs have some potential for interactions with
sugammadex, although these affinities were 120-fold
to 700-fold lower than that for the aminosteroid
neuromuscular blocking agent rocuronium. The same
method was used in the study of Zwiers et al. [26],
where 300 drugs were tested and modeled to deter-
mine possibile drug interacts with sugammadex. Of
all of these tested compounds, only three were considered
possible for the displacement of rocuronium from sugam-
madex: toremifene, fusidic acid and flucloxacillin [26, 27].
According to these model-based chemical studies and the
theoretical molecular features, sugammadex appears
highly selective for aminosteroid neuromuscular blocking
agents, with the minimal possibility of interactions with
other drugs.
This study was designed to investigate the in vivo
significance of previously observed in vitro interactions
between dexamethasone and sugammadex [21, 22] in
surgical patients undergoing general anaesthesia, where
sugammadex was used to reverse rocuronium-induced
NMB. To explore this potential interaction we hypothe-
sized that less sugammadex is available for rocuronium
binding. In agreement, the plasma rocuronium concentra-
tions increases to a lesser extent after sugammadex
application in patients treated with dexamethasone, in
comparison to patients without dexamethasone treatment.
Methods
This prospective, single-blinded, randomized, parallel-
group, single-centre study was retrospectively registered
with the Australian and New Zealand Clinical Trial
Registry (ANZCTR) and was assigned trial number
ACTRN12612000245897 and universal trial number
U1111-1128-5104. The study protocol was approved by
the National Medical Ethics Committee of the Ministry
of Health of the Republic of Slovenia (permit number
161/02/11). Written informed consent was obtained
from the patients enrolled. The study was performed at
the Department of Anaesthesiology and Intensive
Therapy, University Medical Centre Ljubljana, Slovenia,
and conducted according to the Declaration of Helsinki,
International Conference on Harmonization Guidelines
and Good Clinical Practice.
Subject recruitment
The patients included were aged 18 years or more, with
American Society of Anaesthesiologists physical status I-
III, and were anesthetized for elective abdominal or uro-
logical surgery for which they needed tracheal intubation
and deep NMB throughout the procedure. The exclusion
criteria were: lack of consent, diagnosed neuromuscular
disease, anticipated difficult intubation, severe kidney
failure, personal or family history of malignant hyper-
thermia, known allergic reaction to any of the anaes-
thetics used, pregnancy or nursing, and taking oral
contraceptives or drugs already known to interact with
sugammadex. The patients who complied with all of the
inclusion and exclusion criteria were randomly assigned
to the control (granisetron) group and the observed
(dexamethasone) group. Randomization was performed
using random number-generator, and the allocation
sequence was concealed from the researcher enrolling
and assessing participants in sequentially externally
numbered, opaque and sealed envelopes.
Study procedure
On arrival in the operating room, standard monitoring
with pulse oximetry, capnography and electrocardiog-
raphy was installed, followed by insertion of an intra-
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arterial cannula for invasive blood pressure measure-
ment. The depth of anaesthesia was followed according
to the bispectral index.
Anaesthesia was induced with propofol (1–2 mg/kg; IV)
or etomidate (2 mg/kg; IV) and fentanyl (3–5 μg/kg; IV).
Before administration of the neuromuscular blocking
agent, their neuromuscular transmission was assessed by
acceleromyography, using a TOF-Watch® SX neuromus-
cular transmission monitor (Organon Ireland Ltd, Merck
and Co, Inc, Swords, Dublin, Ireland), at the ulnar nerve
at 15 s intervals until stabilization. During the TOF-
Watch® SX calibration period, a laryngeal mask was
inserted and anaesthesia was maintained with inhaled
sevoflurane (minimal alveolar concentration ≥1) in an air/
oxygen mixture with intermittent positive-pressure venti-
lation of the patient’s lungs to achieve a normal end-tidal
carbon dioxide (4.5–5.5 kPa). Calibration of the TOF was
performed according to good clinical practice guidelines
[28]. Rocuronium (0.6 mg/kg; IV) was then administered,
and when an adequate depth of NMB was reached (ac-
cording to TOF measurements), tracheal intubation was
performed, and intermittent positive-pressure ventilation
continued with sevoflurane in an air/oxygen mixture with
additional boluses of fentanyl (2–3 μg/kg; IV). The
NMB was further assessed throughout the procedure
using repetitive TOF stimulation, and IV rocuronium
0.1–0.2 mg/kg was administered accordingly, to main-
tain the desired depth of NMB. This was maintained until
the reversal of NMB using sugammadex (200 mg; IV), for
recovery of the T4/T1 TOF ratio to ≥0.9 at the end of
anaesthesia.
All of the patients received an antiemetic for prophy-
laxis of postoperative nausea and vomiting. Following
intubation, the patients were randomized by the opening
of an opaque envelope containing a computer-generated
allocation to either control group (received granisetron
(1 mg; IV) at the beginning of the operation) or dexa-
methasone group – these patients received dexametha-
sone (0.15 mg/kg; IV) 5 min to 10 min before the
administration of sugammadex. Both prior to sugamma-
dex administration and after NMB reversal to TOF ≥0.9, a
blood sample (4 ml) was withdrawn from the intra-arterial
line. Tubes without additives were used, the samples were
centrifuged, and the serum frozen at −20 °C until analysis.
Determination of plasma rocuronium and dexamethasone
concentrations
The rocuronium concentrations in the plasma samples
obtained from the patients in the control and dexametha-
sone groups were determined at the Institute of Forensic
Medicine, Faculty of Medicine, University of Ljubljana.
For this purpose, a liquid chromatography–tandem mass
spectrometry (LC-MS/MS) method was developed and
validated according to recent recommendations for
method validation in analytical toxicology [29], which were
based on the International Conference on Harmonization,
Harmonized Tripartite Guideline Validation of Analytical
Procedures. The sugammadex–rocuronium complex disso-
ciated on the chromatographic columns during the liquid
chromatography, and therefore the data for rocuronium
indicate the total (captured plus free) rocuronium in the
plasma.
The plasma dexamethasone concentrations in the
samples from patients in the dexamethasone group were
determined at the Institute of Clinical Chemistry and
Biochemistry, University Medical Centre Ljubljana. A
competitive colorimetric enzyme-linked immunosorbent
assay was used for the analyses (ID Laboratories Inc.,
London, Canada), with the limit of quantification of
50 μg/l, and a within-run variability of <10 %. All of
these samples were analyzed as one batch.
Statistical analysis
The primary study endpoint was the time from sugam-
madex administration to NMB reversal, measured as the
recovery of muscle strength to a TOF ratio ≥0.9. The
secondary endpoints were the ratios between the dexa-
methasone (test group) and rocuronium concentrations
(both groups) after NMB reversal to a TOF ratio >0.9
versus the dexamethasone and rocuronium con-
centrations, respectively, prior to administration of
sugammadex.
Due to the lack of available literature on blood concen-
trations of dexamethasone and rocuronium, sample size
was determined on the basis of previous sugammadex
studies [30–34] where the mean time from moderate or
profound rocuronium-induced NMB to NMB reversal
with a TOF ratio >0.9 was studied. We considered a 20 %
increase in the time to NMB reversal to be clinically
relevant. Assuming a power of 80 % for a two-sided test of
difference in proportion at the 5 % significance level, and
allowing for a 10 % drop-out due to protocol violation, we
calculated that 33 patients per group were required.
The demographic data of the control and dexamethasone
groups were compared using Students’ t-tests or
Mann–Whitney U-tests for continuous variables, or
χ2 tests for nominal variables. For paired measurements
(rocuronium and dexamethasone concentrations), paired
t-tests or Wilcoxon signed rank tests were used.
Two models of multiple linear regression were con-
structed, the first to examine the relationship between
dexamethasone and the time to reversal of the
rocuronium-induced NMB with sugammadex, and the
second to determine whether dexamethasone affects the
ratio between the rocuronium concentrations after NMB
reversal versus before sugammadex administration.
Beside the group (control/dexamethasone) variable, two
(depth of NMB before dexamethasone administration
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(baseline TOF, with TOF 1–4) and sugammadex dose)
or three (depth of NMB before dexamethasone adminis-
tration (baseline TOF, with TOF 1–4), sugammadex dose
and rocuronium dose per hour of operation) independ-
ent variables were added in the first and second regres-
sion model, respectively. To meet the assumptions of
the linear regression model, sugammadex dose and
rocuronium dose per hour of operation were logarith-
mically transformed.
The effects of the time interval between the two blood
samples that were withdrawn and the sugammadex dose
on the ratio of dexamethasone concentrations after
NMB reversal versus before sugammadex administration
were assessed within the dexamethasone group using
one-way analysis of variance (ANOVA). In the ANOVA
model, the independent variables were categorized as
follows: the patients who received 2–3 mg/kg sugamma-
dex vs. 3–4 mg/kg sugammadex, and the patients in
whom the time between withdrawal of blood samples
was ≤5 min vs. >5 min.
Results
Based on the power analysis, 65 patients were randomized
to either the control (granisetron) or dexamethasone
group, of whom 62 completed the study per protocol
(Fig. 1). One patient in the control group was excluded
from the study due to a surgical complication, and
technical difficulties when measuring the TOF were en-
countered with two patients from the dexamethasone
group. In two patients among those who completed the
study (one in the control and one in the dexamethasone
group), a TOF ratio ≥0.8 but not ≥0.9 was reached, so
these two patients were excluded from further analysis.
The baseline characteristics of the control and dexa-
methasone groups are summarized in Table 1. There
were no significant differences in these parameters
between the two treatment groups.
Dexamethasone effect on time to reversal of the NMB
by sugammadex
For the time to TOF ratio ≥0.9, there were no statistically
significant differences between the control (121 ± 61 s)
and the dexamethasone group (125 ± 57 s; P = 0.760).
The first multiple linear regression model analysed the
variables predicting the time to TOF ratio ≥0.9 and
included group (control or dexamethasone), depth of
NMB before sugammadex administration, and sugam-
madex dose (logarithmically transformed). The model
was statistically significant (P = 0.049) and explained
about 10 % of the population variance of the outcome
(Table 2). The depth of NMB before administration of
sugammadex had a statistically significant negative
weight (Beta = −0.268; P = 0.038), which indicated that in
patients with a lower baseline TOF (before sugamma-
dex administration) the time to NMB reversal to a
TOF ratio ≥0.9 tended to be longer. The weights for
sugammadex dose (Beta = −0.237; P = 0.069) and group
(control versus dexamethasone group; Beta = −0.054;
P = 0.676) were not statistically significantly different
from zero.
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram of study cohort. TOF – Train-of four
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The effects of dexamethasone on rocuronium
concentrations ratio
When comparing the ratio of the rocuronium concen-
trations after NMB reversal to the concentration before
sugammadex administration, we did not find any statisti-
cally significant differences between the control and
dexamethasone groups (control: mean 1.17 ± 0.19; dexa-
methasone: mean 1.09 ± 0.15; P = 0.090; Fig. 2).
With the second multiple linear regression model,
we investigated the factors that could affect the afore-
mentioned ratio. This model was statistically signifi-
cant (P = 0.005) and explained about 20 % of the
population variance of the outcome (Table 3). Sugam-
madex dose (Beta = −0.375; P = 0.004) and rocuronium
dose per hour of operation (Beta = −0.366; p = 0.007)
were statistically significant predictors whereas the
depth of NMB before sugammadex administration
(Beta = −0.089; p = 0.483) and addition of dexametha-
sone (Beta = −0.186; p = 0.131) did not statistically sig-
nificantly predict the rocuronium concentrations ratio.
Analysis of factors affecting plasma dexamethasone
concentration
Although there was a statistically significant difference
(p < 0.001) between the dexamethasone concentrations
before sugammadex administration (810 ± 283 μg/l) and
after NMB reversal to a TOF ratio ≥0.9 (604 ± 208 μg/l,
Fig. 3), ANOVA did not reveal significant effects of
sugammadex dose (2–3 mg/kg (n = 23) vs. 3–4 mg/kg
(n = 8); p = 0.729) or time between the withdrawal of
blood samples (≤5 min (n = 12) vs. >5 min (n = 19);
p = 0.524).
Discussion
In the present study, we have shown that previously ob-
served in vitro interactions between sugammadex and
dexamethasone [21, 22] are not reflected in the recovery
from rocuronium-induced NMB by sugammadex in
anesthetized patients.
We first quantified the possible binding of dexametha-
sone to sugammadex by measuring the time to TOF
ratio ≥0.9. Our results show, that the time to TOF
ratio ≥0.9 is not delayed by the administration of
dexamethasone before sugammadex reversal of
rocuronium-induced NMB, which is in accordance with
recent clinical studies by Buonanno et al. [24] and Gulec
et al. [23]. In both of these studies dexamethasone was
used for prevention of postoperative nausea and vomiting.
Buonanno et al. retrospectively compared the effect of
8 mg dexamethasone at the induction of anesthesia or just
before sugammadex adminstration on reversal time in
adults [24] while Gulec et al. prospecitvely studied the
Table 1 Baseline characteristics for the control and dexamethasone patient groups





Age [years (interquartile range)] 62 (52–68) 63 (52–71) 0.826
Gender: male [n (%)] 16 (51.6) 16 (51.6) 1.000
Body weight [kg (interquartile range)] 75 (70–88) 74 (63–85) 0.301
American Society of Anesthesiologists physical status (interquartile range) 2 (2–3) 2 (2–3) 0.836
Surgery duration (intubation-extubation time) [h (±standard deviation)] 2.42 (±0.83) 2.35 (±0.54) 0.790
Rocuronium dose per hour [mg/h (±standard deviation)] 41.83 (±12.21) 42.01 (±16.79) 0.525
Sugammadex dose [mg/kg (±standard deviation)] 2.62 (±0.48) 2.81 (±0.58) 0.291
Depth of NMBb before sugammadex administration [TOFc (interquartile range)] 0 (0–2) 0 (0–1) 0.070
aData are medians (interquartile range) or means (±standard deviation)
bNMB neuromuscular block
cTOF train-of-four stimulation
Table 2 Summary of multiple regression analysis for variables predicting the time to TOF ratio ≥0.9 (n = 60)
B SE (B) β P-value F (df) P-value Adj. R2
Model 2.786 (3, 56) 0.049* 0.083
Constant 69.881 39.279 0.081
Group −6.293 14.981 −0.054 0.676
Baseline TOF value −15.145 7.112 −0.268 0.038*
Sugammadex dosea 72.250 38.928 0.237 0.069
Abbreviations: B variable estimate, SE(B) standard error of the variable estimate, β standardized estimate, F (df) F statistics (degrees of freedom), Adj. R2 adjusted
proportion of the variance explained by the model, TOF train of four
aLogarithmically transformed; *p < 0.05
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reversal time of sugammadex on rocuronium induced
NMB in children who received 0.5 mg/kg of dexametha-
sone at the induction of anesthesia [23]. In comparison to
these studies, we used low-dose fixed dexamethasone con-
centration (0.15 mg/kg) just prior to sugammadex admin-
istration. This dosing of dexamethasone was chosen based
on previous studies where it effectively reduced the inci-
dence of postoperative nausea and vomiting [35–37],
while the timing of its administration was potentially less
appropriate, as we (like Buonanno et al. [24]) endeavoured
to achieve higher dexamethasone concentrations in the
serum of patients. It was thus not possible to assess the in-
cidence of postoperative nausea and vomiting, which
might have provided some further insight into the second
type of interaction that is possible with sugammadex, i.e.,
capturing. Should one be able to eliminate the time factor
in the dexamethasone administration, it would be of inter-
est to evaluate these results in the context of our previous
study, where sugammadex attenuated dexamethasone
effects on functional innervation and on constitutive
interleukin-6 (IL-6) secretion in in vitro co-cultures of hu-
man muscle cells and rat spinal cord explants [21].
We then further evaluated possible interaction between
dexamethasone and sugammadex by determining plasma
dexamethasone (dexamethasone group) and rocuronium
concentrations (both groups) before sugammadex admin-
istration and after NMB reversal.
We observed a drop in dexamethasone concentration,
which could be explained by its binding by sugammadex;
however, as the NMB reversal was not delayed compared
to the control group, and furthermore, the sugammadex
dose did not affect the magnitude of the dexamethasone
drop, we concluded it is more plausible the dexametha-
sone was bound by plasma proteins (especially albumin)
and underwent a re-distribution to peripheral compart-
ments, rather than being bound solely by sugammadex.
In order to indirectly detect the interactions between
dexamethasone and sugammadex, we measured the
plasma rocuronium concentrations, which increased
after sugammadex administration. This observation is in
agreement with previous studies [38–40] and can indeed
be explained by rapid rocuronium encapsulation by
sugammadex, which would create a concentration gradi-
ent that favours the movement of the remaining free
rocuronium away from the neuromuscular junction and
into the plasma. We observed that in comparison to the
control group, in the patients who received dexametha-
sone, the rise in rocuronium concentrations was smaller,
although this difference did not reach statistical signifi-
cance. Therefore, our hypothesis (i.e., that because of the
interaction between dexamethasone and sugammadex,
less sugammadex is available for binding to rocuronium,
and consequently the plasma rocuronium concentrations
would increase to a lesser extent compared to the control
group) was not confirmed.
Based on this clinical evaluation of NMB reversal by
sugammadex and the laboratory determinations of the
dexamethasone and rocuronium concentrations, we
could not translate the results from our in vitro studies
Fig. 2 Dexamethasone effects on rocuronium concentration ratios
in the control and dexamethasone groups. Box plots for the
measurements of the ratio of rocuronium concentration after NMB
reversal (to a TOF ratio ≥0.9) to rocuronium concentration before
sugammadex administration, in patients in control and
dexamethasone groups (as indicated). Data are medians with
interquartile range
Table 3 Summary of multiple regression analysis for variables predicting the rocuronium concentrations ratio (n = 60)
B SE (B) β P-value F (df) P-value Adj. R2
Model 4.242 (4, 55) 0.005* 0.180
Constant 2.303 0.339 0.000
Group −0.066 0.043 −0.186 0.131
Baseline TOF value −0.015 0.022 −0.089 0.483
Sugammadex dosea −0.345 0.115 −0.375 0.004*
Rocuronium dose per hour of operationa −0.214 0.076 −0.366 0.007*
Abbreviations: B variable estimate, SE(B) standard error of the variable estimate, β standardized estimate, F (df) F statistics (degrees of freedom), Adj. R2 adjusted
proportion of the variance explained by the model, TOF train of four
aLogarithmically transformed; *p < 0.05
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into clinical practice. In co-cultures of human muscle
cells innervated with rat embryonic spinal cord explants,
sugammadex diminished dexamethasone effects on
constitutive IL-6 secretion [21], and high dexamethasone
concentrations attenuated the reversal of rocuronium-
induced NMB by sugammadex [22]. We can therefore
assume that in human plasma, the binding between
dexamethasone and sugammadex does not promote
clinically significant consequences in terms of NMB re-
versal delay. There could be at least two possible expla-
nations for this.
First, the plasma dexamethasone concentrations
determined in in vivo after low-dose dexamethasone
administration (0.15 mg/kg) are lower than those used
in previous in vitro studies [21, 22]. The mean plasma
concentration of dexamethasone (before administration
of sugammadex) was approximately five times lower
than dexamethasone concentration that resulted in
the peak in vitro effect (10 μM). The latter had re-
portedly been reached only after high-dose dexametha-
sone treatment, which can be used during cardiac surgery
[22, 41–45]. Hence, the sufficiently high plasma dexa-
methasone concentration might be critical for its com-
plexion with sugammadex.
Second, under in vivo conditions, there are several
physiological factors that can affect the binding between
dexamethasone and sugammadex that cannot be pre-
dicted by in vitro conditions. This can be substantially
explained by looking into the pharmacokinetics of the
drugs involved. First, the greater portion of intravenous
dexamethasone, 75 ± 4 %, is bound mainly by albumin
[46] and the remainder, the unbound dexamethasone is
theoretically suitable for interaction with sugammadex.
Furthermore, the apparent volume of distribution for
dexamethasone (normalized for 70 kg bodyweight) would
be 65.7 ± 17.3 l [47], such that expected serum concentra-
tion for 70 kg person (receiving altogether 10.5 mg dexa-
methasone) would be 160 ± 61 μg/l (0.4 ± 0.2 μM), which
is considerably lower than our measured mean concentra-
tion just before the reversal of NMB (810 μg/l ± 283 μg/l,
which corresponds to 2.1 μM±0.7 μM) and mean con-
centration after NMB reversal to TOF ratio ≥0.9 by
sugammadex (604 ± 208 μg/l, which corresponds to 1.8 ±
0.6 μM). We therefore assume that both blood samples
were drawn before steady state was reached and our aim
– to achieve high plasma level of dexamethasone – was
therefore accomplished. This allows us to speculate about
the impact of higher dexamethasone doses (that could
conceivably be used in certain clinical conditions and that
have also been used in in vitro studies [21, 22]) on sugam-
madex reversal of NMB. To elaborate even further we can
take into account the pharmacokinetic profile of sugam-
madex, which has a volume of distribution similar to
extracellular fluid (11–14 l) and it does not bind to plasma
proteins [48]. The sugammadex dose of 200 mg for a
70 kg bodyweight theoretically results in the plasma
concentration of 18182 – 14285 μg/l (8.3–6.6 μM). Unfor-
tunately, sugammadex plasma concentration was not
determined in our study and one can only speculate
whether these theoretical steady-state concentrations
reflect the actual plasma concentration, especially 2 min
after administration. Furthermore, as previous studies
have demonstrated, 2 min after administration of 2 mg/kg
sugammadex the total (rocuronium-bound and free)
plasma concentrations of sugammadex was about 20000–
30000 μg/l (13.8–9.2 μM) [40, 49], which is also higher
than theoretical steady-state concentrations. Considering
these calculations, and further assuming all dexametha-
sone molecules would be captured by sugammadex imme-
diately after its administration, about 77–85 % of surplus
sugammadex would still remain available for rocuronium
binding (expected steady-state concentration for a 70 kg
bodyweight after receiving 0.6 mg rocuronium (mean
volume of distribution of 14.2 l [50]) would be
2957 μg/l, which corresponds to 5.6 μM). Finally, be-
sides the high protein binding properties dexametha-
sone lacks the charged quaternary nitrogen on the
ammonium group of neuromuscular blocking agents
that binds to the carboxyethyl side chains of sugam-
madex [51]. This explains the aforementioned low
association rate constant between dexamethasone and
sugammadex (less than 1000 mol/l) in contrast to
high rocuronium-sugammadex association rate constant
(1.79 × 107 mol/l) [26] and further supports assumption
that clinically important NMB delay due to dexametha-
sone would be highly unlikely.
Fig. 3 Comparison of rocuronium and dexamethasone
concentration ratios in the dexamethasone group. Box plots for the
measurements of the ratios of rocuronium and dexamethasone
concentrations after NMB reversal (to a TOF ratio ≥0.9) to the
rocuronium and dexamethasone concentrations, respectively, before
sugammadex administration, in the dexamethasone group. Data are
medians with interquartile range
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Nevertheless, we cannot extrapolate our findings on corti-
costeroids in general. Namely, study by Zwiers et al. has re-
vealed that dexamethasone shows the lowest displacement
potential among corticosteroids [26], so based on the
present and previous studies [21–24] the clinically relevant
interactions between sugammadex and other corticosteroids
cannot be excluded and further studies are required.
When interpreting our findings, one should take into
consideration the limitations of the study. As already men-
tioned, sample size was determined on the basis of previ-
ous sugammadex studies [30–34] instead of conducting a
preliminary study. Next, the sugammadex dose was not ad-
justed to depth of NMB (TOF count), but was rather gen-
eralized to all patients (one vial, 200 mg), which was then
later calculated to mg/kg sugammadex for statistical ana-
lysis. To compensate for this, the data were analyzed using
a regression model to adjust for different sugammadex
concentrations. Furthermore, enrolment of another group
of patients in whom NMB reversal would be promoted by
acetylcholinesterase inhibitors (and not by sugammadex)
would have helped us distinguish between the decrement
in dexamethasone concentration due to its re-distribution
to peripheral compartments and to the decrement attribut-
able to its complexing with sugammadex.
Regarding the choice of the TOF ratio ≥0.9 threshold, it
should be noted that we could have analyzed complete data
without excluding the two patients who had not reached
the threshold. The simplest approach would be to assign
the maximum observed time (optionally increased by a
small random value) to those two patients. A more valid
approach would be to analyze the data as censored, e.g.,
using a Cox regression model. We tried both approaches
and obtained essentially identical results to those reported
(in terms of statistical significance of the model as a
whole as well as of the individual predictors). The ef-
fect of omitting the two patients was therefore negli-
gible, so we opted for using the established threshold
and applying a simpler data-analysis method.
Conclusions
To conclude, the addition of dexamethasone in anesthe-
tized patients did not delay NMB reversal by sugammadex.
Although we observed a drop in plasma dexamethasone
and a rise in plasma rocuronium concentrations after
sugammadex administration, this did not appear to be a
direct consequence of the displacement interaction between
dexamethasone and sugammadex. Therefore, the significant
interaction between dexamethasone and sugammadex that
has been previously demonstrated in in vitro biological
models was not confirmed in anesthetized patients in vivo,
probably due to several intrinsic factors that influence
pharmacodynamics and pharmacokinetics of both dexa-
methasone and rocuronium. The interaction is therefore
limited to such extent that is clinically irrelevant.
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